Announcements Trials
Browse Landscape

Status

Recruiting 97Active not recruiting 57Completed 22Not yet recruiting 16Terminated 10Withdrawn 3Enrolling by invitation 3Suspended 2Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Pancreatic Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasms 2Melanoma 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neuroblastoma 1Myelodysplastic Syndromes 1Meningioma 1Mastocytosis, Systemic 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Mast-Cell 1Leukemia 1Insulinoma 1Hypoglycemia 1Hyperinsulinism 1

Interventions

dodecyl maltoside 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × Urinary Bladder Neoplasms × 90 days × Clear all
NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

CG Oncology, Inc.

Available
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡